144 related articles for article (PubMed ID: 37410014)
21. Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature.
Blackman A; Boutin A; Shimanovsky A; Baker WJ; Forcello N
J Oncol Pharm Pract; 2018 Jul; 24(5):393-397. PubMed ID: 28523950
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors.
Al-Nawakil C; Willems L; Mauprivez C; Laffy B; Benm'rad M; Tamburini J; Fontaine H; Sogni P; Terris B; Bouscary D; Moachon L
Leuk Lymphoma; 2014 Jul; 55(7):1670-4. PubMed ID: 24090500
[No Abstract] [Full Text] [Related]
23. Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia.
Malbora B; Avci Z; Ozbek N
Drug Chem Toxicol; 2012 Oct; 35(4):463-6. PubMed ID: 22149271
[TBL] [Abstract][Full Text] [Related]
24. L-Asparaginase and steroids-associated hypertriglyceridemia successfully treated with plasmapheresis in a child with acute lymphoblastic leukemia.
Solano-Páez P; Villegas JA; Colomer I; Gutierrez MD; Fernandez-Teijeiro A
J Pediatr Hematol Oncol; 2011 Apr; 33(3):e122-4. PubMed ID: 21399528
[TBL] [Abstract][Full Text] [Related]
25. Genetic markers for treatment-related pancreatitis in a cohort of Hispanic children with acute lymphoblastic leukemia.
Grimes AC; Chen Y; Bansal H; Aguilar C; Perez Prado L; Quezada G; Estrada J; Tomlinson GE
Support Care Cancer; 2021 Feb; 29(2):725-731. PubMed ID: 32447501
[TBL] [Abstract][Full Text] [Related]
26. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.
Rank CU; Lynggaard LS; Als-Nielsen B; Stock W; Toft N; Nielsen OJ; Frandsen TL; Tuckuviene R; Schmiegelow K
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013399. PubMed ID: 33038027
[TBL] [Abstract][Full Text] [Related]
27. The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
Tong WH; Pieters R; de Groot-Kruseman HA; Hop WC; Boos J; Tissing WJ; van der Sluis IM
Haematologica; 2014 Nov; 99(11):1716-21. PubMed ID: 25150254
[TBL] [Abstract][Full Text] [Related]
28. How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.
Burke MJ
Future Oncol; 2014 Dec; 10(16):2615-27. PubMed ID: 24983955
[TBL] [Abstract][Full Text] [Related]
29. Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute Lymphoblastic Leukemia: Current Perspectives.
Gibson A; Hernandez C; Tejada FNH; Kawedia J; Rytting M; Cuglievan B
Paediatr Drugs; 2021 Sep; 23(5):457-463. PubMed ID: 34351604
[TBL] [Abstract][Full Text] [Related]
30. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Kloos RQH; Pieters R; Jumelet FMV; de Groot-Kruseman HA; van den Bos C; van der Sluis IM
J Clin Oncol; 2020 Mar; 38(7):715-724. PubMed ID: 31922920
[TBL] [Abstract][Full Text] [Related]
31. Asparaginase: How to Better Manage Toxicities in Adults.
Pourhassan H; Douer D; Pullarkat V; Aldoss I
Curr Oncol Rep; 2023 Jan; 25(1):51-61. PubMed ID: 36449117
[TBL] [Abstract][Full Text] [Related]
32. Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management.
Sandley M; Angus J
Leuk Lymphoma; 2023 Apr; 64(4):776-787. PubMed ID: 36781296
[TBL] [Abstract][Full Text] [Related]
33. Successful management of extreme hypertriglyceridemia in a child with acute lymphoblastic leukemia by temporarily omitting dexamethasone while continuing asparaginase.
Tong WH; Pieters R; van der Sluis IM
Pediatr Blood Cancer; 2012 Feb; 58(2):317-8. PubMed ID: 22162400
[No Abstract] [Full Text] [Related]
34. Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
Cohen H; Bielorai B; Harats D; Toren A; Pinhas-Hamiel O
Pediatr Blood Cancer; 2010 May; 54(5):703-6. PubMed ID: 20063421
[TBL] [Abstract][Full Text] [Related]
35. Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study.
Wolthers BO; Frandsen TL; Baruchel A; Attarbaschi A; Barzilai S; Colombini A; Escherich G; Grell K; Inaba H; Kovacs G; Liang DC; Mateos M; Mondelaers V; Möricke A; Ociepa T; Samarasinghe S; Silverman LB; van der Sluis IM; Stanulla M; Vrooman LM; Yano M; Zapotocka E; Schmiegelow K;
Lancet Oncol; 2017 Sep; 18(9):1238-1248. PubMed ID: 28736188
[TBL] [Abstract][Full Text] [Related]
36. Characterization of hypertriglyceridemia induced by L-asparaginase therapy for acute lymphoblastic leukemia and malignant lymphoma.
Tozuka M; Yamauchi K; Hidaka H; Nakabayashi T; Okumura N; Katsuyama T
Ann Clin Lab Sci; 1997; 27(5):351-7. PubMed ID: 9303174
[TBL] [Abstract][Full Text] [Related]
37. Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group.
Defina M; Lazzarotto D; Guolo F; Minetto P; Fracchiolla NS; Giglio F; Forghieri F; Vitale A; Chiaretti S; Papayannidis C; Piccini M; Mulè A; Bocchia M; Leoncin M; Gurrieri C; Aprile L; Lunghi M; Bonifacio M; Pasciolla C; Cerrano M; Fumagalli M; Foà R; Candoni A
Leuk Res; 2022 Nov; 122():106963. PubMed ID: 36155352
[No Abstract] [Full Text] [Related]
38. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase.
Bodmer M; Sulz M; Stadlmann S; Droll A; Terracciano L; Krähenbühl S
Digestion; 2006; 74(1):28-32. PubMed ID: 16988508
[TBL] [Abstract][Full Text] [Related]
39. PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia
Rausch CR; Marini BL; Benitez LL; Elias A; Burke PW; Bixby D; Perissinotti AJ
Leuk Lymphoma; 2018 Mar; 59(3):617-624. PubMed ID: 28718698
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM
J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
